Kogavant (Ticagrelor)

Kogavant (ticagrelor) is an antiplatelet agent used in several cardiovascular conditions.

• Acute coronary syndrome (ACS): reduces the risk of cardiovascular death, myocardial infarction and stroke in patients presenting with ACS.
• Post‑myocardial infarction: lowers the incidence of thrombotic cardiovascular events after an MI.
• Secondary prevention of atherothrombotic events: helps prevent recurrent ischemic events in patients with established atherosclerotic disease.

• Ticagrelor reversibly binds to the platelet P2Y12 ADP receptor, blocking ADP‑mediated activation of the G_i protein pathway. This inhibition prevents platelet aggregation and thrombus formation without requiring metabolic activation, providing rapid and consistent antiplatelet activity across a broad patient population.

Ticagrelor may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Dyspnea: shortness of breath, often occurring early in therapy.
• Bleeding: including bruising, nosebleeds, gastrointestinal hemorrhage.
• Headache: mild to moderate intensity.
• Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects

• Severe bleeding: intracranial or life‑threatening hemorrhage.
• Hypersensitivity reactions: rash, angioedema, anaphylaxis.
• Elevated serum uric acid: may precipitate gout attacks.

Before initiating ticagrelor therapy, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

• Renal impairment: assess renal function and consider dose adjustment.
• Hepatic disease: use with caution in patients with moderate to severe liver dysfunction.
• Concomitant anticoagulants: increased bleeding risk; monitor coagulation parameters.
• History of bleeding disorders: evaluate bleeding risk before prescribing.
• Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ticagrelor can interact with several medicines, altering its antiplatelet effect or increasing bleeding risk.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ticagrelor plasma levels and heighten bleeding.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy, increasing thrombotic risk.

Moderate Interactions (Monitor Closely)

• Anticoagulants (warfarin, DOACs): additive anticoagulant effect; monitor for signs of bleeding.
• NSAIDs or aspirin: combined use raises gastrointestinal bleeding risk.
• Statins metabolized by CYP3A4 (e.g., simvastatin): may increase statin exposure; consider dose reduction.